Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

NCT05776069

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Vega Therapeutics, Inc
Enrollment	116 participants

Key Eligibility Criteria

Inclusion (13)

- Subjects, 18 to 60 years of age, inclusive for Parts 1 and 2
- Subjects, 12 to 60 years of age, inclusive for Parts 3 and 5
- No clinically significant laboratory, ECG, or vital signs results.
- Subjects with VWD who are symptomatic, defined as having a history of bleeding or bruising.
- Hemoglobin level e 8 g/dL and platelet count e 150 × 109/L at Screening.

... and 8 more (see full listing online)

Exclusion (2)

- Baseline FVIII activity \> 50 IU/dL.
- Any acute, clinically significant bleeding event requiring surgical or procedural intervention within 7 days prior to receiving study drug.

Locations (25 total)

Orthopedic Institute for Children (UCLA), Los Angeles, California, United States
UC Davis Medical Center, Sacramento, California, United States
University of Colorado School of Medicine, Aurora, Colorado, United States
... and 22 more locations